(Q53901726)

English

Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

author name string

P Chanson

1

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

A Leselbaum

2

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

J Blumberg

3

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

G Schaison

4

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

publication date

1 May 2000

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

2

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

4

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

269-276

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

https://scigraph.springernature.com/pub.10.1023/a:1009961116472

0 references

Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gallstones during octreotide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995)

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sandostatin LAR in acromegalic patients: long-term treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of octreotide on glucose tolerance in acromegaly.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation therapy of acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the somatostatin analogue SMS 201-995 on faecal fat excretion in acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cholelithiasis and acromegaly: therapeutic strategies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective examination of octreotide-induced gall-bladder changes in acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acromegaly: what constitutes optimal therapy?

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus statement: benefits versus risks of medical therapy for acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Octreotide treatment of acromegaly. A randomized, multicenter study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular biology of somatostatin receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The short and long-term effects of octreotide on calcium homeostasis in patients with acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surgical management of acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11081148

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1009961116472

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11081148

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53901726&oldid=1391147555"